In addition, most previous retrospective studies focused on individual traits of HER2-low breast cancer, which makes understanding HER2-low breast cancer similar to collecting pieces of findings and might lead to a discrepancy in clinicopathological features and clinical outcomes extracted from different studies [8–15]. This evidence concerns the gene ERBB2 and breast carcinoma.